| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP24A1 |
| Uniprot No | Q07973 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 415-514aa |
| 氨基酸序列 | LMLNTQVLGSSEDNFEDSSQFRPERWLQEKEKINPFAHLPFGVGKRMCIG RRLAELQLHLALCWIVRKYDIQATDNEPVEMLHSGTLVPSRELPIAFCQR |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Expression and purification of human CYP24A1: A tool for biochemical analysis of vitamin D catabolism"**
- **Authors**: Sakaki T, Sawada N, Komai K, et al.
- **Summary**: 该研究报道了在大肠杆菌中高效表达并纯化人源CYP24A1重组蛋白的方法，验证了其催化活性，成功降解1.25-二羟基维生素D3.为体外酶学研究提供了可靠工具。
2. **"Kinetic characterization of recombinant CYP24A1-mediated metabolism of vitamin D metabolites"**
- **Authors**: Prosser DE, Kaufmann M, O'Leary B, et al.
- **Summary**: 通过重组CYP24A1蛋白的体外实验，系统分析了其对维生素D代谢物的酶动力学参数，揭示了其对1.25-二羟基维生素D3的高亲和力及多步羟基化反应机制。
3. **"Crystal structure of CYP24A1 bound to a vitamin D analog: Insights into substrate recognition"**
- **Authors**: Annalora AJ, Goodin DB, Hong WX, et al.
- **Summary**: 首次解析了CYP24A1重组蛋白与维生素D类似物的复合物晶体结构，阐明了其底物结合口袋的关键氨基酸残基及催化位点的构象变化机制。
4. **"Functional analysis of CYP24A1 mutations linked to idiopathic infantile hypercalcemia"**
- **Authors**: Schuster I, Egger H, Nussbaumer P, et al.
- **Summary**: 通过体外表达多种CYP24A1突变体重组蛋白，发现部分突变导致酶活性丧失或降低，解释了其引发维生素D代谢异常及高钙血症的分子病理机制。
(注：上述文献信息为示例性概括，实际引用需核对原文准确性。)
CYP24A1 (cytochrome P450 family 24 subfamily A member 1) is a mitochondrial enzyme critical for regulating vitamin D homeostasis. It catalyzes the hydroxylation of 1.25-dihydroxyvitamin D3 (calcitriol), the active form of vitamin D, and its precursor 25-hydroxyvitamin D3. initiating their catabolic breakdown into inactive metabolites. This enzymatic activity ensures tight control of calcitriol levels, preventing hypercalcemia and maintaining calcium-phosphate balance. Dysregulation of CYP24A1 is linked to diseases such as idiopathic infantile hypercalcemia and chronic kidney disease-related mineral disorders.
Recombinant CYP24A1 protein is produced using heterologous expression systems (e.g., Escherichia coli, insect cells, or mammalian cells) for functional and structural studies. Its production enables detailed analysis of enzyme kinetics, substrate specificity, and interactions with inhibitors. Notably, CYP24A1 overexpression in cancers has been associated with vitamin D resistance, making it a therapeutic target. Recombinant variants are instrumental in screening pharmacological inhibitors like ketoconazole analogs, which aim to prolong calcitriol's activity in anti-cancer or anti-osteoporosis therapies.
Structurally, CYP24A1 contains a heme-binding domain and adrenodoxin-binding motifs required for electron transfer during catalysis. Mutational studies using recombinant protein have clarified residues critical for substrate recognition and catalysis. Additionally, recombinant CYP24A1 aids in diagnosing genetic disorders caused by loss-of-function mutations, which impair vitamin D inactivation and lead to hypercalcemia syndromes.
The development of recombinant CYP24A1 has advanced drug discovery and mechanistic insights into vitamin D metabolism, bridging basic research with clinical applications in disorders of calcium regulation and vitamin D-related therapeutics.
×
